Androgen deprivation therapy (ADT), the mainstay systemic treatment for high risk non-metastatic (M0) and metastatic (M1) prostate cancer is associated with bone loss and increased fracture risk. The STAMPEDE trial tested the addition of zoledronic acid (ZA) ± docetaxel (with prednisolone) to ADT. Both regimens may impact bone health. However, long-term fracture incidence remains uncertain.
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data
Annals of Oncology | | C. Jones, P. Dutey-Magni, L.R. Murphy, M.L. Murray, J.E. Brown, E. McCloskey, M. Brown, C.L. Amos, D.C. Gilbert, R.J. Jones, W. Cross, D. Matheson, R. Millman, M.K.B. Parmar, G. Attard, M.R. Sydes, L.C. Brown, N.D. James, N.W. Clarke, A. Sachdeva, STAMPEDE Trial Investigators
Topics: prostate-cancer, chemotherapy, clinical-trials